51 results about "Human Females" patented technology

An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.

A prosthesis for addressing pelvic organ prolapse in females comprises a frame fabricated from a shape memory material that supports a thin, flexible mesh sheet in a stretched condition when the frame is unconstrained. The mesh sheet is formed with two finger receiving pockets proximate its posterior periphery to be used by the surgeon in steering the prosthesis to a desired disposition within the pelvic basin. The frame is shaped so as to conform to and be supported by bone structures and muscle tissue in the pelvic basin while providing needed support to pelvic organs to maintain them in a proper position. The use of a shape memory material allows the prosthesis to be rolled or folded into a reduced size for ease of placement through a small incision in the wall of the vagina, but that springs back to its memorized shape following deployment from a delivery sheath.

Disclosed is a test device to detect pregnancy in a human female subject, the test device comprising:

• • an assay means to measure the absolute or relative amount of hCG in a sample from the subject;
  • an assay means to measure the absolute or relative amount of FSH in a sample from the subject;
  • and an assay means to measure the absolute or relative amount of one or more progesterone metabolites in a sample from the subject.

The invention provides compositions and methods suitable for ameliorating female sexual dysfunction, and in particular, female sexual arousal disorder. In preferred embodiments, the invention provides a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a penetration enhancer, a polymer thickener, a lipophilic component, and an acidic buffer system. In other embodiments, the invention provides a method of treating female sexual arousal disorder by applying an effective dose of a topical semisolid prostaglandin composition to the anterior wall of the vagina.

An improved comfort aide system for providing breastfed babies with the comforting sensory experience of non-feeding suckling at a breast resembling that of a mother's breast in: smell, form, feel and function. Comprising a main body portion of latex or silicone material, filled with liquid or other filler substance, shaped like a human female breast. A cover having the tactility of human skin encloses the main body. The cover may be saturated, sprayed or sprinkled with mom's breast milk. Cover dries and retains the smell of mom and her milk. Cover has a rear opening flap for permitting removal of the main body. Cover has a hole placed opposite to opening flap for nipple placement. The nipple, comprising areola, teat, and nipple base is attached through cover hole and is suckled by baby in the same manner baby would suckle to mom's natural lactating breast.

A prosthesis for addressing pelvic organ prolapse in females comprises a frame comprising first and second segments or halves fabricated from a shape memory material that together support a thin, flexible sheet in a stretched condition when the frame is unconstrained. The frame is shaped so as to conform to and be supported by bone structures and muscle tissue in the pelvic basin while providing needed support to pelvic organs to maintain them in a proper position. The use of a shape memory material allows the prosthesis to be rolled or folded into a reduced size for ease of placement through a small incision in the wall of the vagina, but that springs back to its memorized shape following deployment from a. delivery sheath. By providing a two-piece segmented frame, removal of the frame structure post implantation of the prosthesis is facilitated.

Ovarian germ-line-competent embryonic stem cells (GLC-ESC) are cultured, either in the presence or absence of a compound having estrogenic activity. The GLC-ESC are either collected prior to specific commitment or are permitted to remain in the culture medium for a time sufficient to develop into oocytes, and the oocytes may be fertilized by adding sperm to the culture medium. The fertilized oocytes may be permitted to develop into embryos, which may be transferred into the uterus of an adult human female or frozen for later use. The invention provides a method for obtaining by in vitro fertilization an embryo that is genetically related to a human female who is not producing oocytes.

The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.

A device for intraoperative sizing of a human female breast during resizing and/or shaping of the breast composes: a (a) substantially hemispherical, rigid, cup-shaped foraminous body, i.e., a foraminous cup, defining a desired size and shape of the breast; and (b) a rim member to which the foraminous cup is affixed.

The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.

A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months. A method of increasing the rate and number of euploid oocytes may include administering an androgen for at least about four consecutive weeks. In addition, a method of increasing male fetus sex ratio may comprise raising baseline androgen levels in a female prior to or at time of embryo implantation.

A prosthesis for addressing pelvic organ prolapse in females comprises a frame fabricated from a shape memory material that supports a thin, flexible sheet in a stretched condition when the frame is unconstrained. The frame is shaped so as to conform to and be supported by bone structures and muscle tissue in the pelvic basin while providing needed support to pelvic organs to maintain them in a proper position. The use of a shape memory material allows the prosthesis to be rolled or folded into a reduced size for ease of placement through a small incision in the wall of the vagina, but that springs back to its memorized shape following deployment from a delivery sheath.

A method of determining the estimated date of implantation of an embryo may include testing a sample of a body fluid from a pregnant human female subject so as to obtain data indicative of the concentration of human chorionic gonadotrophin (hCG) in the sample, and calculating an estimated date of implantation from the hCG concentration data.

The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.

Disclosed is a method of detecting a retarded cycle in a human female subject experiencing same, the method comprising the steps of obtaining a sample of body fluid from the subject on each of a plurality of, but not less than three, days; testing each of the plurality of samples to determine the concentration therein of at least one analyte of significance in the ovulatory cycle; comparing a result determined from said testing with a predetermined threshold value; and, if said determined result is different from the threshold value; declaring the cycle, during which the samples were taken, to be a retarded cycle.

Disclosed is a test device to detect pregnancy In a human female subject, the test device comprising: an assay means to measure the absolute or relative amount of hCG m a sample from the subject; an assay means to measure the absolute or relative amount of FSH in a sample from the subject; and m assay means to measure the absolute or relative amount of one or mere progesterone metabolites I>> a sample from the subject.

Method of early detection of risk of infertility and ovarian aging in and treatment of a human female who has not experienced infertility and is not otherwise indicated to have premature ovarian aging. A number of CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and a testing regimen is performed only when the determined number of CGG repeats on one of the FMR1 gene alleles is less than 26. The testing regimen includes periodically measuring serum level of a hormone related to fertility, such as Anti-Müllerian Hormone, Follicle Stimulating Hormone and/or estradiol over a period of about three to eight years and, after each measurement, determining if the measured serum level is less than a set confidence interval for a human female of the same age of the female. If so, the human female is treated for premature ovarian aging.

A development toy that is made of soft, light BPA-free silicone and/or clear plastic that is one solid piece with no moving parts or attachments. The toy is intended to sooth an infant and/or toddler when frustrated from teething pains in their gum and oral area. The toy will be made in various different animal, bird, fish and machine shapes with appendages in the shape of a human female “mother's” nipple to provide the familiar sensation of sucking on mother's breast. The toy will be made in non-toxic soft materials, clear plastic and/or silicone resembling candy in bright soft pastels in a cartoon formed body with easily gripping areas. All parts of the toy provide a safe form of soothing and controlled breathing areas.

A method of preconditioning ovulation induction in a human female comprises of administering an androgen, for example, DHEA, for at least about four consecutive months. DHEA may be administered along with high dose gonadotrophins in ovulation induction treatments. Moreover, DHEA may be administered with follicle stimulating hormone, human menopausal gonadotrophin, norethindrone acetate, leuprolide acetate, and human chorionic gonadotrophin in ovulation induction treatments.